Indomethacin 100Mg Suppository: Indomethacin 100 mg administered per rectum after induction of anesthesia, prior to oocyte retrieval. Indomethacin Group
Paracetamol / Acetaminophen: Paracetamol (Acamol) 1,000 mg administered intravenously after induction of anesthesia, prior to oocyte retrieval.
Study summary
This is a randomized controlled trial evaluating the efficacy of preoperative analgesic medications - Indomethacin (100 mg per rectum) and Paracetamol/Acamol (1,000 mg intravenously) - for pain management during oocyte retrieval in women undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Women undergoing oocyte retrieval for IVF or ICSI
* Age 18-45 years
* ASA physical status classification I or II
* Willing and able to provide written informed consent
Exclusion Criteria:
* Known allergy or hypersensitivity to Indomethacin, any NSAID, or Paracetamol
* History of gastrointestinal bleeding or peptic ulceration
* Renal impairment (GFR \< 30 ml/min/1.73m² or Creatinine \> 1.04 mg/dL)
* Hepatic impairment (ALT \> 55 U/L, AST \> upper limit of normal, ALP \> upper limit of normal, Total Bilirubin \> 1.2 mg/dL, or Albumin \< 3.5 g/dL)
* Participation in another clinical trial that may interfere with the outcomes of this study
Primary outcome measure(s)
Postoperative Pain Intensity — From immediately post-procedure up to 3 days after oocyte retrieval Pain intensity assessed using the Numerical Rating Scale (NRS), where 0 = no pain and 10 = worst imaginable pain. Pain is measured immediately after the procedure, every 15 minutes for 2 hours post-retrieval, prior to discharge, and 1-3 days after oocyte retrieval. Scores are compared across the three study arms.
Trial sites (1)
Facility
City
Region
Status
Western Galilee Hospital, IVF unit
Nahariya
Israel
More Western Galilee Hospital-Nahariya trials in Israel
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
